New drug hope for rare bone marrow cancer
NCT ID NCT04517851
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 17 times
Summary
This early-phase trial tests whether elotuzumab can help control myelofibrosis, a rare bone marrow cancer. The study includes 15 adults with a specific genetic mutation (JAK2) whose disease is at intermediate or higher risk. The main goal is to see if the drug improves blood cell counts, reduces spleen size, and eases symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.